GP方案单用与联合氨磷汀方案在晚期恶性肿瘤化疗不良反应中的比较

Comparison of adverse reactions in advanced malignant tumor chemotherapy of GP regimen with joint program of amifostine

目的通过比较GP(吉西他滨+顺铂)方案与氨磷汀联合GP方案的不良反应,为氨磷汀的合理应用及药学监护提供理论参考。方法收集我院肿瘤科2011年7月至2013年12月应用GP方案的患者42例,氨磷汀联合GP方案的患者37例,分别记录2组患者每周期化疗后的不良反应,并进行对比分析。结果与GP方案组比较,氨磷汀联合GP方案组的恶心呕吐发生率明显升高(P<0.01),并出现严重的消化道反应(P<0.01),头晕和低血压发生率增加(P<0.05)。结论联合氨磷汀化疗易出现严重的恶心呕吐及低血压等不良反应。临床除常规监测血常规和肝肾功能外,化疗期间应积极预防消化道反应,每天监测血压,及时对症支持治疗,以保证患者用药安全。

AIM To provide a theoretical reference for the rational use and pharmaceutical care of amifostine by comparing adverse reactions of GP （gemcitabine plus cisplatin） and amifostine combined with GP. METHODS Patients in which 42 used GP, 37 used GP and amifostine were collected in the department of oncology in our hospital from July 2011 to December 2013. Each week after chemotherapy the adverse reactions of patients in 2 groups were recorded, ana- lyzed and compared. RESULTS The regimen amifostine in combination with GP significantly increased the rate of nau- sea and vomiting（ P 〈 0.01 ）, occurring serious gastrointestinal reaction（ P 〈 0.01 ）, and dizziness and hypotension rate were higher（ P 〈 0.05 ）, compared whih GP regimen. CONCLUSION Amifostine combined with GP in chemotherapy can easily induce serious adverse reactions such as nausea, vomiting and hypotension. In addition to regular monitoring of blood, liver and kidney function, actively preventing digestive tract reaction, daily monitoring of blood pressure and timely symptomatic treatment is needed in order to ensure medication safety of patients.